A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases.
Whether the differences in the clinical picture and in the pathogenesis between rheumatoid arthritis (RA) and ankylosing spondylitis (AS) will lead to different therapeutic approaches is unclear at present. Since anti-TNF-alpha agents and other biologics are not efficacious in all patients new developments are clearly needed.
Kalden
J R
JR
Abteilung für Molekulare Immunologie, Nikolaus-Fiebiger-Zentrum, Erlangen, Germany. jkalden@molmed.uni-erlangen.de
Braun
J
J
D000818:Animals; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D001691:Biological Therapy / Q000379:methods / Q000639:trends*; D004195:Disease Models, Animal; D006801:Humans; D011994:Recombinant Proteins; D012219:Rheumatology / Q000639:trends; D013167:Spondylitis, Ankylosing / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha